Back to top
more

ABIOMED, Inc. (ABMD)

(Delayed Data from NSDQ)

$271.75 USD

271.75
1,074,902

+6.98 (2.64%)

Updated May 3, 2019 04:00 PM ET

After-Market: $271.72 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Headquartered in Danvers, MA and founded in 1981, ABIOMED Inc. (ABMD) is engaged in developing, manufacturing and marketing of medical products, designed to assist or replace the pumping function of the failing heart. Abiomed’s main product line - Impella - comprises Impella 2.5, Impella 5.0, Impella LD, Impella CP and Impella RP.

Why Abiomed (ABMD) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Integra (IART) Q1 Earnings Top Estimates, Margins Expand

Integra's (IART) updated 2022 financial guidance calls for strong year-over-year organic growth.

QIAGEN (QGEN) Q1 Earnings Surpass Estimates, 2022 View Up

QIAGEN (QGEN) exited first-quarter 2022 with better-than-expected results on strength in the non-COVID product portfolio driving the top line.

Abiomed (ABMD) Q4 Earnings and Revenues Surpass Estimates

Abiomed's (ABMD) strength in Impella product revenues drives its Q4 top line.

Integra LifeSciences (IART) Tops Q1 Earnings and Revenue Estimates

Integra (IART) delivered earnings and revenue surprises of 8.82% and 3.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Trina Mukherjee headshot

MedTech Stocks' Apr 28 Earnings Roster: ABMD, SYK & More

The MedTech companies' Q1 results are likely to reflect solid rebound in base business sales. Let's see how ABMD, SYK, BAX and DXCM are poised ahead of their earnings releases.

Here's Why You Should Retain Allscripts (MDRX) Stock For Now

Investors continue to be optimistic about Allscripts Healthcare Solutions (MDRX) owing to its strategic alliances.

Abiomed (ABMD) to Report Q4 Earnings: What's in the Cards?

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q4 sales.

Here's Why You Should Retain Integra (IART) Stock For Now

Investors are optimistic about Integra (IART), given the strength in its CSS arm and notable product launches.

Globus Medical (GMED) Stock Fell on Preliminary Q1 Sales Results

Globus Medical's (GMED) Q1 preliminary sales results reflect an increase in procedural volumes along with growth in Enabling Technologies business.

Here's Why You Should Retain Baxter (BAX) Stock For Now

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio and regulatory clearances.

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, contraction in gross margin is a woe.

Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio

Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

Here's Why You Should Hold on to Illumina (ILMN) Stock For Now

Investors are optimistic about Illumina's (ILMN) strategic collaborations and strong international sales.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

Zacks Industry Outlook Highlights Alcon, STERIS and Abiomed

Alcon, STERIS and Abiomed have been highlighted in this Industry Outlook article.

Merit Medical's (MMSI) Latest Launch to Boost Patient Outcome

Merit Medical's (MMSI) latest well-designed tray is expected to simplify the thoracostomy procedure and reduce treatment time, especially in critical situations.

Here's Why You Should Retain Bio-Rad (BIO) Stock For Now

Investors are optimistic about Bio-Rad (BIO) owing to a recovery in most of its key global markets as well as an uptick in demand for COVID-related products.

Patterson Companies (PDCO) Moves Up 12.5%: What's Driving It?

Investors are optimistic about Patterson Companies' (PDCO) robust segmental performance and strong prospects in the dental space.

Thermo Fisher (TMO) Debuts GMP-Manufactured Cas9 Protein

Thermo Fisher's (TMO) Gibco CTS TrueCut Cas9 Protein to support genome editing for research and manufacturing applications.

Here's Why You Should Hold on to CONMED (CNMD) Stock Now

CONMED (CNMD) continues to gain momentum from a solid product portfolio and strong General Surgery business. However, data security threats linger.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy Despite Industry Headwinds

The Zacks Medical - Instruments industry is growing on R&D investments. ALC, STE and ABMD are set to gain the most. Yet, demand for non-COVID businesses is on the decline with the new COVID variant disrupting the trend.

McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Catalent's (CTLT) Latest Manufacturing Suites to Boost Capacity

Catalent's (CTLT) latest site expansion is expected to significantly boost its business.

Henry Schein (HSIC) Stock Moves Up 20.6%: What's Driving It?

Henry Schein's (HSIC) stock rallied on strong fourth-quarter performance and bullish 2022 EPS guidance.